Interview With James Hallifax

This week in psychedelic business news: Cybin acquires a Phase…

Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy

When it comes to treating mental health conditions with psychedelic therapy, one of the most promising compounds is DMT, the main ingredient in the brew ayahuasca. While DMT may have many potential advantages over other similar compounds such as psilocybin, for example, its short duration of effect, the hallucination can be very intense.

It is an open question whether the mental health benefits we see from psychedelic therapy are due to the experience one undergoes when having a hallucination, or whether it comes strictly from the drug’s effects on the brain. If it is the latter, then hypothetically speaking, we could create a version of DMT that does not cause a hallucination.

Enter Psilera Biosciences.

Psilera is a psychedelic medicines company working to create next-generation psychedelics for use in therapeutic settings. Specifically, they aim to create non-psychedelic versions of classical psychedelics such as psilocybin, LSD and DMT.

PSIL-002 is Psilera’s version of non-hallucinogenic DMT. They recently completed a pre-clinical trial in mice that showed that their version of DMT was safe and non-psychedelic. Now they have to show that their version of DMT can treat depression and addiction, starting with alcoholism.

If Psilera’s DMT can treat these mental health conditions equally as well as regular DMT, but without the intense hallucination, then PSIL-002 would probably be the better compound.

It is exciting to see Psilera’s scientists working on answering the following questions:

Can DMT treat depression?
Can psychedelics help with depression?
Can psychedelics help with Mental Health?

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Video editing: @themyaholy @Psy_holy

#DMT #DEPRESSION #PSYCHEDELICTHERAPY

In this video, I discuss how MindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF. 🔥

MindMed has had a impressive run up in 2020. The MMED stock is up nearly 1,130% and what we all wonder is : Could MindMed Stock keep on rising? With a larger psychedelic pipeline than Compass Pathways (CMPS), MindMed has made huge advancements in 2020, one of which is its LSD Neutralizer Technology To Shorten and Stop LSD Trips, which is groundbreaking news for all players in the psychedelic medicines industry.

MindMed has a handful of exciting programs in the works, some of which have important milestones coming up this year. Project Lucy is one of these programs, using therapeutic doses of LSD to treat anxiety disorders. If this gets the go-ahead from regulators, it will proceed with a clinical trial investigating LSD for anxiety disorders. If that happens, the mindmed stock could get a big boost. Another boost could be MindMed’s potential uplisiting on to the Nasdaq.

Currently, the MindMed Stock trades on the Canadian exchange NEO under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ.

Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMedStock #MindMed #MMED #MMEDF